z-logo
open-access-imgOpen Access
Dystrophic Cutaneous Calcification and Metaplastic Bone Formation due to Long Term Bisphosphonate Use in Breast Cancer
Author(s) -
Ali Murat Tatlı,
Şeyda Gündüz,
Sema Sezgin Göksu,
Deniz Arslan,
Mükremın Uysal,
Cumhur İbrahim Başsorgun,
Hasan Şenol Çoşkun
Publication year - 2013
Publication title -
case reports in oncological medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.173
H-Index - 7
eISSN - 2090-6714
pISSN - 2090-6706
DOI - 10.1155/2013/871917
Subject(s) - medicine , bisphosphonate , calcification , dystrophic calcification , breast cancer , cancer , dentistry , dermatology , osteoporosis , pathology
Bisphosphonates are widely used in the treatment of breast cancer with bone metastases. We report a case of a female with breast cancer presented with a rash around a previous mastectomy site and a discharge lesion on her right chest wall in August 2010. Biopsy of the lesion showed dystrophic calcification and metaplastic bone formation. The patient's history revealed a long term use of zoledronic acid for the treatment of breast cancer with bone metastasis. We stopped the treatment since we believed that the cutaneous dystrophic calcification could be associated with her long term bisphosphonate therapy. Adverse cutaneous events with bisphosphonates are very rare, and dystrophic calcification has not been reported previously. The dystrophic calcification and metaplastic bone formation in this patient are thought to be due to long term bisphosphonate usage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom